Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific ...
BioNTech reported Q1 revenue of $192.23 million, surpassing the consensus of $177.40 million. Cash and investments totaled 15.85 billion euros as of March 31, 2025. Geopolitical tensions, Fed ...
BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1, and mRNA ...
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Conference call and webcast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results